Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.
Lipshultz
Steven E
SE
Lipsitz
Stuart R
SR
Orav
Endel John
EJ
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000453:epidemiology / Q000473:pathology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000453:epidemiology / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D011929:Razoxane / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D015871:Scientific Misconduct; D012680:Sensitivity and Specificity; D015996:Survival Rate
D011929:Razoxane